Seer, Inc. Special Committee Rejects Unsolicited Acquisition Proposal from CEO

On July 20, 2026, Seer, Inc. announced that a Special Committee of its Board of Directors unanimously rejected an unsolicited, non-binding acquisition proposal from its Chair and CEO, Omid Farokhzad, M.D. The proposal, originally received on July 1, 2026, sought to acquire all outstanding shares of Seer’s Class A common stock for $2.45 per share in cash, plus two separate contingent value rights (CVRs). The Special Committee, comprised of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D., determined that the offer was not in the best interests of stockholders. Following a review with independent advisors, the committee concluded that the proposal significantly undervalues the company and its long-term growth prospects. Specifically, the committee noted that the included CVRs—intended to let stockholders benefit from future technological developments—were insufficient to capture the full value of Seer's proteomic technology and market potential. Seer continues to operate as a pioneer in deep, unbiased proteomics with its Proteograph Product Suite.